Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: International Conference on Prevention & Infection Control (ICPIC 2011)

Open Access Poster presentation

Economic burden of ventilator associated pneumonia in a developing country

E Alp1*, G Kalin2, R Coskun2, M Sungur2, M Guven2 and M Doganay2

  • * Corresponding author: E Alp

Author Affiliations

1 Infectious Diseases and Clinical Microbiology, Erciyes University, Kayseri, Turkey

2 Erciyes University, Kayseri, Turkey

For all author emails, please log on.

BMC Proceedings 2011, 5(Suppl 6):P65  doi:10.1186/1753-6561-5-S6-P65


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/5/S6/P65


Published:29 June 2011

© 2011 Alp et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction / objectives

There is limited data about the economic burden of ventilator associated pneumonia (VAP) in developing countriesTo investigate incidence, risk factors, etiological agents, antimicrobial susceptibility rates and economic burden of VAP in a medical intensive care unit (MICU) of a developing country.

Methods

All patients on mechanical ventilation were followed up during one year in MICU.

Results

During the one-year period, 159 patients were followed up.Mean age was 61.82±16.81. VAP developed in 96 (60%) patients with 37.2/1000 ventilation days.The mean APCAHE II score was 24.32±5.94, and there was no difference between VAP and non-VAP patients.Median mechanical ventilation days for non-VAP patients were 3 days (1-15 days).Mortality rate for non-VAP patients was 88.5%, and the median time for death was 4th day of hospitalization.Median time for VAP development was 5.5 days (2-25 days).Acinetobacter baumannii (42%) and Pseudomonas aeruginosa (20%) were the most common pathogens.All microorganisms were multi-resistant.Imipenem resistance of A.baumannii and P.aeruginosa was 92% and 71%, respectively.The most significant risk factors for VAP were stay in hospital before MICU (OR:3.11) and length of stay in MICU (1.47). Mortality rate for VAP-patients was 80% and there was no statistically difference between the mortality rates of VAP and non-VAP patients.Median total cost of non-VAP patients in ICU was 2315 Euro, whereas it was 6308 Euro in VAP patients. Also, cost of ICU (253&908 Euro), antibiotics (230&810 Euro), laboratory (370&979 Euro) and clinical (371&878 Euro) were higher in VAP patients.

Conclusion

The cost of VAP is approximately three-fold higher than non-VAP patients. Infection control standards should be assessed and rigorously reinforced in “limited-resources” countries.

Disclosure of interest

None declared.